All peptides

Thymosin Alpha 1

Also known as Zadaxin

An immune-modulating peptide used internationally for hepatitis, sepsis, and adjunct cancer care.

Regulatory status
Approved in 30+ countries; not FDA approved
Half-life
~2 hours
Route
Subcutaneous
Evidence
Limited human trials or approved outside the US

Mechanism of action

Enhances T-cell maturation and dendritic cell function via TLR signaling.

Studied and reported uses

  • Immune support
  • Chronic viral infection adjunct
  • Sepsis adjunct

Dosing information

Clinical range1.6 mg twice weekly

Ranges are reported from literature and clinical labeling for reference only. They are not a dosing recommendation.

Side effects

  • Injection-site reaction
  • Transient flu-like symptoms

Research evidence

Sepsis RCT

Improved immune markers and trend toward lower mortality.